Statistical design and analysis of stability studies

Statistical Design and Analysis of Stability Studies

Volumn , Issue , 2007, Pages 1-331

  Chow, Shein Chung ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44949206968     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (205)

1. Ahn, H., Chen, J.J., and Lin, T.Y.D. (1995). Classification of batches in a stability study. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 256–261.
2. Ahn, H., Chen, J., and Lin, T.D. (1997). A two-way analysis of covariance model for classification of stability data. Biometrical Journal, 39, 559–576.
3. Altan, S. and Raghavarao. (2003). A note on kinetic modeling of stability data and implications on pooling. Journal of Biopharmaceutical Statistics, 13, 425–430.
4. Anderson, R.L. (1982). Analysis of Variance Components. Unpublished lecture notes. University of Kentucky, Lexington.
5. Bakshi, M. and Singh, S. (2002). Development of validated stability-indicating assay methods: critical review. Journal of Pharmaceutical and Biomedical Analysis, 28, 1011–1040.
6. Bancroft, T.A. (1964). Analysis and inference for incompletely specified models involving the use of preliminary test(s) of significance. Biometrics, 20, 427–442.
7. Bar, R. (2003). Statistical evaluation of stability data: criteria for change-over-time and data variability. Journal of Pharmaceutical Science and Technology, 57(5), 369–377.
8. Barron, A.M. (1994). Use of fractional factorial (or matrix) designs in stability analysis. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, 475–481.
9. Bergum, J.S. (1990). Constructing acceptance limits for multiple stage tests. Drug Development and Industrial Pharmacy, 16, 2153–2166.
10. Bohidar, N.R. and Peace, K. (1988). Pharamceutical formulation development. In Biopharmaceutical Statistics for Drug Development, Peace, K., Ed. Marcel Dekker, New York, pp. 149–229.
11. Box, G.E.P. and Lucas, H.L. (1959). Design and experiments in non-linear situation. Biometrics, 46, 77–90.
12. Brandt, A. and Collings, B.J. (1989). The development of estimators for parameters in a random effects model for shelf-life. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 98–99.
13. Carstensen, J.T. (1990). Drug Stability. Marcel Dekker, New York.
14. Carstensen, J.T. and Rhodes, C. (2000). Drug Stability: Principles and Practices. Marcel Dekker, New York.
15. Carstensen, J.T., Franchini, M., and Ertel, K. (1992). Statistical approaches to stability protocol design. Journal of Pharmaceutical Sciences, 81, 303–308.
16. Carter, R.L. and Yang, M.C.K. (1986). Large sample inference in random coefficient regression model. Communications in Statistics: Theory and Methods, 15, 2507–2525.
17. CBP. (2001). Expiration dates: compliance guidelines. The Script, California Board of Pharmacy, July, 2001, p. 1.
18. CDER. (2004). CDER Report to the Nation: 2004. Center for Drug Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
19. Chambers, D. (1996). Matrixing/bracketing US industry views. Proceedings of EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing Building on the ICH Stability Guideline. EFPIA, Brussels.
20. Chen, C. (1996). US FDA’s perspective of matrixing and bracketing. Proceedings of EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing Building on the ICH Stability Guideline. EFPIA, Brussels.
21. Chen, J.J., Ahn, H., and Tsong, Y. (1997). Shelf life estimation for multi-factor stability studies. Drug Information Journal, 31, 573–587.
22. Chen, J.J., Hwang, J.S., and Tsong, Y. (1995). Estimation of the shelf-life of drugs with mixed effects models. Journal of Biopharmaceutical Statistics, 5, 131–140.
23. Chen, W.J. and Tsong, Y. (2003). Significance levels for stability pooling test: a simulation study. Journal of Biopharmaceutical Statistics, 13, 355–374.
24. Chen, Y.Q., Pong, A., and Xing, B. (2003). Rank regression in stability analysis. Journal of Biopharmaceutical Statistics, 13, 463–479.
25. Chow, S.C. (1992). Statistical Design and Analysis of Stability Studies. Presented at the 48th Conference on Applied Statistics, Atlantic City, NJ.
26. Chow, S.C. (1997). Pharmaceutical validation and process controls in drug development. Drug Information Journal, 31, 1195–1201.
27. Chow, S.C. and Ki, F.Y.C. (1997). Statistical comparison between dissolution profiles of drug products. Journal of Biopharmaceutical Statistics, 7, 241–258.
28. Chow, S.C. and Liu, J.P. (1995). Statistical Design and Analysis in Pharmaceutical Science. Marcel Dekker, New York.
29. Chow, S.C. and Liu, J.P. (2000). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd Edition, Marcel Dekker, New York.
30. Chow, S.C. and Pong, A. (1995). Current issues in regulatory requirements of drug stability. Journal of Food and Drug Analysis, 3, 75–85.
31. Chow, S.C., Pong, A., and Chang, Y.W. (2006). On traditional Chinese medicine clinical trials. Drug Information Journal, 40, 395–406.
32. Chow, S.C. and Shao, J. (1989). Test for batch-to-batch variation in stability analysis. Statistics in Medicine, 8, 883–890.
33. Chow, S.C. and Shao, J. (1990a). Estimating drug shelf-life in NDA stability studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 190–195.
34. Chow, S.C. and Shao, J. (1990b). On the difference between the classical and inverse methods of calibration. Journal of the Royal Statistical Society, C, 39, No. 2, 219–228.
35. Chow, S.C. and Shao, J. (1991). Estimating drug shelf-life with random batches. Biometrics, 47, 1071–1079.
36. Chow, S.C. and Shao, J. (2002a). Statistics in Drug Research. Marcel Dekker New York, Chapter 4.
37. Chow, S.C. and Shao, J. (2002b). On the assessment of similarity for dissolution profiles of two drug products. Journal of Biopharmaceutical Statistics, 12, 311–321.
38. Chow, S.C. and Shao, J. (2003). Stability analysis with discrete responses. Journal of Biopharmaceutical Statistics, 13, 451–462.
39. Chow, S.C. and Shao, J. (2007). Stability analysis for drugs with multiple ingredients. Statistics in Medicine. 26. In press.
40. Chow, S.C., Shao, J., and Hu, O.Y.P. (2002a). Assessing sensitivity and similarity in bridging studies. Journal of Biopharmaceutical Statistics, 12, 385–400.
41. Chow, S.C., Shao, J., and Wang, H. (2002b). Probability lower bounds for USP/NF tests. Journal of Biopharmaceutical Statistics, 12, 79–92.
42. Chow, S.C., Shao, J., and Wang, H. (2003). Sample Size Calculation in Clinical Research. Marcel Dekker, New York.
43. Chow, S.C. and Wang, S.G. (1994). On the estimation of variance components in stability analysis. Communications in Statistics: Theory and Methods, 23, 289–303.
44. Connors, K.A., Amidon, G.L., and Stella, V.J. (1986). Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists. John Wiley and Sons, New York.
45. CPMP (1998). Note for Guidance on Stability Testing of Existing Active Substances and Related Finished Products. Committee for Proprietary Medicinal Products, EMEA, London.
46. Davies, O.L. (1980). Note on regression with corrected responses. Biometrics, 36, 551–552.
47. Davies, O.L. and Hudson, H.E. (1981). Stability of drugs: accelerated storage tests. In Statistics in the Pharamceutical Industry, Ed Buncher, C.R. and Tsay, J.Y., Eds. Marcel Dekker, New York, pp. 355–395.
48. Davies, O.L. and Hudson, H.E. (1993). Stability of drugs. Part B: Accelerated storage tests. In Statisics in the Pharmaceutical Industry, 2nd ed. Buncher, C.R. and Tsay, J.Y., Eds., Marcel Dekker, New York, 445–480.
49. Dawoodbhai, S., Suryanarayan, E., Woodruff, C., and Rhodes, C. (1991). Optimization of tablet formulation containing talc. Drug Development and Industrial Pharmacy, 17, 1343–1371.
50. Dempster, A.P., Laird, N.M., Rubin, D.B. (1977). Maximum likelihood from incomplete data via the EM algorithm (with discussion). Journal of the Royal Statistical Society, B, 39, 1–38.
51. Dempster, A.P., Rubin, D.B., and Tsitakawa, R.K. (1981). Estimation in covariance components models. Journal of the American Statistical Association, 76, 341–353
52. DeWoody, K. and Raghavarao, D. (1997). Some optimal matrix designs in stability studies. Journal of Biopharmaceutical Statistics, 7, 205–213.
53. Dietz, R., Feilner, K., Gerst, F., and Grimm, W. (1993). Drug stability testing: classification of countries according to climatic zone. Drugs Made in Germany, 36, 99–103.
54. Draper, N.R. and Smith, H. (1981). Applied Regression Analysis, 2nd Ed., Wiley, New York.
55. Easterling, R.G. (1969). Discrimination intervals for percentiles in regression. Journal of the American Statistical Association, 64, 1031–1041.
56. Fahrmeir, L. and Tutz, G. (1994). Multivariate Statistical Modelling Based on Generalized Linear Models. Springer, New York.
57. Fairweather, W.R. (2003). A quantitative assessment of factors influencing the probability of postmarketing out-of-specification observations. Journal of Biopharmaceutical Statistics, 13, 415–423.
58. Fairweather, W.R. and Lin, T.D. (1999). Statistical and regulatory aspects of drug stability studies: an FDA perspective. In International Stability Testing, Mazzo, D., Ed. Interpharm Press, Buffalo Grove, pp. 107–132.
59. Fairweather, W.R., Lin, T.D., and Kelly, R. (1995). Regulatory, design, and analysis aspects of complex stability stdies. Journal of Pharmaceutical Sciences, 84, 1322–1326.
60. Fairweather, W.R., Mogg, R., Bennett, P.S., Zhong, J., Morrisey, C., and Schofield, T.L. (2003). Monitoring the stability of human vaccines. Journal of Biopharmaceutical Statistics, 13, 395–413.
61. FDA. (1987). Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics. Center for Drugs and Biologics, Office of Drug Research and Review, Food and Drug Administration, Rockville, MD.
62. FDA. (1994). Guide to Inspection of Bulk Pharamceutical Chemicals. The U.S. Food and Drug Administration, Rockville, MD.
63. FDA. (1997). Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. The United States Food and Drug Administration, Rockville, MD.
64. FDA. (1998). Guidance for Industry: Stability Testing of Drug Substances and Drug Products (draft guidance). The United States Food and Drug Administration, Rockville, MD.
65. FDA. (2000). Guidance for Industry: Analytical Procedures and Methods Validation (draft guidance). The United States Food and Drug Administration, Rockville, MD.
66. FDA. (2006). FDA Enforcement Report. The U.S. Food and Drug Administration, Rockville, MD, March 8, 2006.
67. Federal Register. (1997). Prescription drug products: levothyroxine sodium. Federal Register, 62, (157), 43553–43537.
68. Fuller, W.A. (1996). Introduction to Statistical Time Series, 2nd ed., Wiley, New York.
69. Garnick, R.I., et al. (1982). Stability indicating high-pressure liquid chromatographic method for quality control of sodium liothyronine and sodium levothyroxine in tablet formulations. In Hormone Drugs, Gueriguian, J.L., Bransome, E.D., and Outschoorn, A.S., Eds. United States Pharmacdpedial Convention, pp. 504–516, Rockville, MD.
70. Gill, J.L. (1978). Design and Analysis of Experiments in Animal and Medical Sciences, Vol. 1, Iowa State University Press, Ames.
71. Gill, J.L. (1988). Repeated measurement: split-plot trend analysis versus analysis of first differences. Biometrics, 44, 289–297.
72. Golden, M.H., Cooper, D., Riebe, M., and Carswell, K. (1996). A matrixed approach to long-term stability testing of pharmaceutical products. Journal of Pharmaceutical Sciences, 86, 240–244.
73. Grimm, W. (1985). Storage conditions for stability testing. Part I: Long term testing and stress tests. Drugs Made in Germany, 28, 196–202.
74. Grimm, W. (1986). Storage conditions for stability testing. Part II: Long term testing and stress tests. Drugs Made in Germany, 29, 39–47.
75. Grimm, W. (1998). Extension of the International Conference on Harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Development and Industrial Pharmacy, 24, 313–325.
76. Grimes, J.A. and Foust, L.B. (1994). Establishing release limits with a random slope stability model. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 498–502.
77. Gumpertz, M. and Pantula, S.G. (1989). A simple approach to inference in random coefficient models. American Statistician, 43, 203–210.
78. Habs, M. (1999). Herbal products: advances in preclinical and clinical development. Drug Information Journal, 33, 993–1001.
79. Hahn, G.J. and Meeker, W.Q. (1991). Statistical Intervals: A Guide for the Practitioner. Wiley, New York.
80. Halperin, M. (1970). On inverse estimation in linear regression. Technometrics, 12, 727–736.
81. Haynes, J.D. (1971). Worldwide virtual temperatures for product stability testing. Journal of Pharmaceutical Sciences, 60, 927–929.
82. Hedayat, A.S. (2001). Optimal Designs. Lecture notes, University of Illinois at Chicago.
83. Hedayat, A.S., Yan, X., and Lin, L. (2006). Optimal designs in stability studies. Journal of Biopharmaceutical Statistics, 16, 35–59.
84. Helboe, P. (1992). New design for stability testing problems: matrix or factorial designs, authorities’ viewpoint on the predictive value of such studies. Drug Information Journal, 26, 629–634.
85. Helboe, P. (1999). Matrixing and bracketing designs for stability studies: an overview from the European perspective. In International Stability Testing, Mazzo, D., Ed. Interpharm Press, Buffalo Grove, IL, pp. 135–160.
86. Hettmansperger, T.P. (1984). Statistical Inferences Based on Ranks. John Wiley, New York.
87. Hettmansperger, T.P. and McKean, J.W. (1998). Robust Nonparametric Statistical Methods. Atnold, New York.
88. Hildreth, G. and Houck, J.R. (1968). Some estimators for a linear model with random coefficients. Journal of the American Statistical Association, 63, 584–595.
89. Ho, C.H., Liu, J.P., and Chow, S.C. (1993). On analysis of stability data. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, 198–203.
90. ICH Q1A. (1993). Stability Testing of New Drug Substances and Products. Tripartite International Conference on Harmonization Guideline Q1A, Geneva.
91. ICH Q1A. (R2) (2003). Stability Testing of New Drug Substances and Products. Tripartite International Conference on Harmonization Guideline Q1A (R2), Geneva.
92. ICH Q2A. (1994). Text on Validation of Analytical Procedures. Tripartite International Conference on Harmonization Guideline Q2A, Geneva.
93. ICH Q3A. (2003). Impurities in New Drug Substances. Tripartite International Conference on Harmonization Guideline Q3A, Geneva.
94. ICH Q6A. (1999). Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Tripartite International Conference on Harmonization Guideline Q6A, Geneva.
95. ICH Q1B. (1996). Photostability Testing of New Drug Substances and Products. Tripartite International Conference on Harmonization Guideline Q1B, Geneva.
96. ICH Q2B. (1996). Validation of Analytical Procedures: Methodology. Tripartite International Conference on Harmonization Guideline Q2B, Geneva.
97. ICH Q3B (1996). Impurities in New Drug Products. Tripartite International Conference on Harmonization Guideline Q3B, Geneva.
98. ICH Q3B (R). (2003). Impurities in New Drug Products. Tripartite International Conference on Harmonization Guideline Q3B (R), Geneva.
99. ICH Q6B. (1999). Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Biotechnological/Biological Products. Tripartite International Conference on Harmonization Guideline Q6B, Geneva.
100. ICH Q1C. (1997). Stability Testing of New Dosage Forms. Tripartite International Conference on Harmonization Guideline Q1C, Geneva.
101. ICH Q5C. (1995). Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. Tripartite International Conference on Harmonization Guideline Q5C, Geneva.
102. ICH Q1D. (2003). Guidance for Industry: Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD.
103. ICH Q1E. (2004) Evaluation of Stability Data. Tripartite International Conference on Harmonization Guideline Q1E, Geneva.
104. ICH Q1F. (2004). Stability Data Package for Registration Applications in Climatic Zones III and IV. Tripartite International Conference on Harmonization Guideline Q1F, Geneva.
105. Jaeckel, L.A. (1972). Estimating regression coefficients by minimizing the dispersion of residuals. Annal. of Mathematical Statistics, 43, 1449–1548.
106. Johnson, R.A. and Wichern, D.W. (1998). Applied Multivariate Statistical Analysis, 3rd ed. Prentice Hall, Upper Saddle River, NJ.
107. Ju, H.L. and Chow, S.C. (1995). On stability designs in drug shelf-life estimation. Journal of Biopharmaceutical Statistics, 5, 201–214.
108. Ju, H.L. and Chow, S.C. (1996). An overview of stability studies. Journal of Food and Drug Analysis, 4, 99–106.
109. Katori, N., Kaniwa, N., Aoyagi, N., and Kojima, S. (1998). A new acceptance plan for the official dissolution test. JP Forum, 7, 166–173.
110. Kellicker, P.G. (2006). Drug expiration dates: how accurate are they? EBSCO Publishing, Ipswich, MA. (http://healthlibrary.epnet.com).
111. Kervinen, L. and Yliruusi, J. (1993). Modeling S-shaped dissolution curves. International Journal of Pharmaceutics, 92, 115–122.
112. Kiermeier, A., Jarrett, R.G., and Verbyla, A.P. (2004). A new approach to estimating shelf-life. Pharmaceutical Statistics, 3(1), 3–11.
113. Kirkwood, T.B.L. (1977). Predicting the stability of biological standards and products. Biometrics, 33, 736–742.
114. Kohberger, R.C. (1988). Manufacturing and quality control. In Biopharmaceutical Statistics for Drug Development, Peace, K., Ed. Marcel Dekker, New York.
115. Kommanaboyina, B. and Rhodes, C.T. (1999). Trends in stability testing with emphasis on stability drug distribution and storage. Drug Development and Industrial Pharmacy, 25, 857–868.
116. Krutchkoff, R.G. (1967). Classical and inverse methods of calibration. Technometrics, 9, 535–539.
117. Kumkumian, C. (1994). International Council for Harmonization Stability Guidelines: Food and Drug Administration regulatory perspective. Drug Information Journal, 28, 635–640.
118. Laird, N.M., Lange, N., and Stram, D. (1987). Maximum likelihood computations with repeated measures: application of the EM algorithm. Journal of the American Statistical Association, 82, 87–105.
119. Laird, N.M. and Ware, J.H. (1982). Random effects models for longitudinal data. Biometrics, 38, 963–974.
120. Lan, K.K.G. and DeMets, D. (1983). Discrete sequential boundaries for clinical trials. Biometrika, 70, 659–663.
121. Langenbucher, F. (1972). Linearization of dissolution rate curves by the Weibull distribution. Journal of Pharmacy and Pharmacology, 24, 979–981.
122. Lee, K.R. and Gagnon, R.C. (1994). Calibration and stability analysis with a simple mixed linear model when the experiment is of a split-plot type. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 435–440.
123. Leeson, L.J. (1995). In vitro/in vivo correlation. Drug Information Journal, 29, 903–915.
124. Lin, J.S. and Chow, S.C. (1992). The estimating of drug shelf-life. Proceedings of the 17th SUCI Conference, Cary, North Carolina, pp. 1292–1297.
125. Lin, K.K. (1990). Statistical analysis of stability study data. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 210–215.
126. Lin, K.K. and Lin, T.Y.D. (1993). Stability of drugs. Part A: Room temperature tests. In Statisics in the Pharmaceutical Industry,2nd ed. Buncher, C.R. and Tsay, J.Y., Eds. Marcel Dekker, New York, pp. 419–444.
127. Lin, T.Y.D. (1994). Applicability of matrix and bracket approach to stability study design. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 142–147.
128. Lin, T.Y.D. (1999a). Statistical considerations in bracketing and matrixing. Proceedings of IBC Bracketing and Matrixing Conference, London.
129. Lin, T.Y.D. (1999b). Study design, matrixing and bracketing. AAPS Workshop on Stability Practices in the Pharmaceutical Industry: Current Issues, Arlington, VA.
130. Lin, T.Y.D. and Chen, C. W. (2003). Overview of stability study designs. Journal of Biopharmaceutical Statistics, 13, 337–354.
131. Lin, T.Y.D. and Fairweather, W.R. (1997). Statistical design (bracketing and matrixing) and analysis of stability data for the US market. Proceedings of IBC Bracketing and Matrixing Conference, London.
132. Lin, T.Y.D. and Tsong, Y. (1991). Determination of significance level for pooling data in stability studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 195–201.
133. 2 as a criterion for assessment of similarity between dissolution profiles. Drug Information Journal, 31, 1225–1271.
134. Liu, J.P., Tung, S.C., and Pong, Y.M. (2006). An alternative approach to evaluation of poolability for stability studies. Journal of Biopharmaceutical Statistics, 16, 1–14.
135. Lu, C.J. and Meeker, W.Q. (1993). Using degradation measures to estimate a time-to-failure distribution. Technometrics, 35, 161–174.
136. Lyon, R.C., Taylor, J.S., Porter, D.A., Prasanna, H.R., and Hussain, A.S. (2006). Stability profiles of drug products extended beyond labeled expiration dates. Journal of Pharmaceutical Sciences, 95, 1549–1560.
137. Ma, M.C., Lin, R.P., and Liu, J.P. (1999). Statistical evaluation of dissolution similarity. Statistica Sinica, 9, 1011–1028.
138. Ma, M.C., Wang, B.B.C., Liu, J.P., and Tsong, Y. (2000). Assessment of similarity between dissolution profiles. Journal of Biopharmaceutical Statistics, 10, 229–249.
139. Mazzo, D.J. (1998). International Stability Testing. Interpharm Press, Buffalo Grove, IL.
140. Mellon, J.I. (1991). Design and Analysis Aspects of Drug Stability Studies When the Product is Stored at Several Temperatures. Presented at the 12th Annual Midwest Statistical Workshop, Muncie, IN.
141. Min, Y. (2004). Semiparametric inferences in stability design. PhD thesis, Univeristy of Florida, Gainesville.
142. Moore, J.W. and Flanner, H.H. (1996). Mathematical comparison of curves with an emphasis on dissolution profiles. Pharmaceutical Technology, 20, 64–74.
143. Morris, J.W. (1992). A comparison of linear and exponential models for drug expiry estimation. Journal of Biopharmaceutical Statistics, 2, 83–90.
144. Muirhead, R.J. (1982). Aspects of Multivariate Statistical Theory. John Wiley and Sons, New York.
145. Murphy, J.R. (1996). Uniform matrix stability study designs. Journal of Biopharmaceutical Statistics, 6, 477–494.
146. Murphy, J.R. (2000). Bracketing design. In Encyclopedia of Biopharmaceutical Statistics, Chow, S.C., Ed. Marcel Dekker, New York, p. 133.
147. Murphy, J.R. and Weisman, D. (1990). Using random slopes for estimating shelf-life. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 196–203.
148. Nordbrock, E. (1989). Statistical Study Design. Presented at the National Stability Discussion Group, October, 1989.
149. Nordbrock, E. (1991). Statistical Comparison of NDA Stability Study Designs. Presented at the Midwest Biopharmaceutical Statistics Workshop, Muncie, IN, May, 1991.
150. Nordbrock, E. (1992). Statistical comparison of stability designs. Journal of Biopharmaceutical Statistics, 2, 91–113.
151. Nordbrock, E. (1994). Design and analysis of stability studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 291–294.
152. Nordbrock, E. (2000). Stability matrix design. In Encyclopedia of Biopharmaceutical Statistics, S. Chow, Ed. Marcel Dekker, New York, pp. 487–492.
153. Nordbrock, E. (2003). Stability matrix designs. In Encyclopedia of Biopharmaceutical Statistics. Ed. S.C. Chow, 2nd Edition, Marcel Dekker, New York, 934–939.
154. Nordbrock, E. and Valvani, S. (1995). PhRMA Stability Working Group. In Guideline for Matrix Designs of Drug Product Stability Protocols, January, 1995.
155. O’Brien, P.C. and Fleming, T.R. (1979). A multiple testing procedure for clinical trials. Biometrics, 35, 549–556.
156. Pena Romero, A., Caramella, C., Ronchi, M., Ferrari, F., and Chulia, D. (1991). Water uptake and force development in an optimized prolonged release formulation. International Journal of Pharmacy, 73, 239–248.
157. Pogany, J. (2006). Stability Studies Assessment Experience. Presented at WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence, China.
158. Polli, J.E., Rekhi, G.S., Augsburger, L.L., and Shah, V.P. (1977). Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartate tablets. Journal of Pharmaceutical Sciences, 86, 670–700.
159. Pong, A. (2000). Expiration dating period. In Encyclopedia of Biopharmaceutical Statistics, Chow, S.C., Ed. Marcel Dekker, New York, pp. 336–342.
160. Pong, A. and Raghavarao, D. (2000). Comparison of bracketing and matrixing designs for a two-year stability study. Journal of Biopharmaceutical Statistics, 10, 217–228.
161. Pong, A. and Raghavarao, D. (2001). Shelf-life estimation for drug products with two components. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA.
162. Pong, A. and Raghavarao, D. (2002). Comparing distributions of shelf lives for drug products with two components under different designs. Journal of Biopharmaceutical Statistics, 12, 277–293.
163. Rahman, R.A. (1992). A comparison of expiration dating period methods. Journal of Biopharmaceutical Statistics, 2, 69–82.
164. Rao, C.R. (1973). Linear Statistical Inference and Its Applications. 2nd Edition, Wiley, New York.
165. Repeto, P. (2000). Some considerations about stability study design. Journal of Biopharmaceutical Statistics, 10, 73–82.
166. Ruberg, S.J. and Hsu, J.C. (1990). Multiple comparison procedures for pooling batches in stability studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 205–209.
167. Ruberg, S.J. and Hsu, J. (1992). Multiple comparison procedures for pooling batches in stability studies. Technometrics, 34, 465–472.
168. Ruberg, S.J. and Stegeman, J.W. (1991). Pooling data for stability studies: testing the equality of batch degradation slopes. Biometrics, 47, 1059–1069.
169. Sathe, P., Tsong, Y., and Shah, V.P. (1996). In vitro dissolution profile comparison: statistics, and analysis, model dependent approach. Pharmaceutical Research, 13, 1799–1803.
170. Schumacher, P. (1974). Aktuelle Fragen zur Haltbarkeit von Arzneimitteln [Current questions on drug stability]. Pharmazeutische Zeitung, 119, 321–324.
171. 2 . Pharmaceutical Research, 15, 889–896.
172. Shao, J. (1999). Mathematical Statistics. Springer, New York.
173. Shao, J. and Chen, L. (1997). Prediction bounds for random shelf-lives. Statistics in Medicine, 16, 1167–1173.
174. Shao, J. and Chow, S.C. (1994). Statistical inference in stability analysis. Biometrics, 50, 753–763.
175. Shao, J. and Chow, S.C. (2001a). Two-phase shelf life estimation. Statistics in Medicine, 20, 1239–1248.
176. Shao, J. and Chow, S.C. (2001b). Drug shelf life estimation. Statistica Sinica, 11, 737–745.
177. Shao, J. and Tu, D. (1995). The Jackknife and Bootstrap. Springer, New York.
178. Silverberg, A. (1997). A comparison of fixed effects model and mixed models for the calculation of shelf-life. Proceedings of the Physical and Engineering Section of the American Statistical Association, Alexandria, VA, pp. 153–162.
179. Snedecor, G.W. and Cochran, W.G. (1980). Statistical Methods, 7th Edition, Iowa State University Press. Ames, Iowa.
180. Stefan, G. and Chantal, B. (2005). The challenges of chemical stability testing of herbal extracts in finished products using state-of-the-art analytical methodologies. Current Pharmaceutical Analysis, 1, 203–215.
181. Sun, Y., Chow, S.C., Li. G., and Chen, K.W. (1999). Assessing distributions of estimated drug shelf-lives in stability analysis. Biometrics, 55, 896–899.
182. SUPAC-IR. (1995). The United States Food and Drug Administration Guideline Immediate Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-IR). Rockville, MD.
183. SUPAC-MR. (1997). The United States Food and Drug Administration Guideline Modified Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-MR). Rockville, MD.
184. SUPAC-SS. (1997). The United States Food and Drug Administration Guideline Nonsterile Semisolid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-SS). Rockville, MD.
185. Swarbrick, J. (1990). Encyclopedia of Pharmaceutical Technology. CRC Press, New York.
186. 1 regression methods. Journal of Pharm. Bm., 11, 843–845.
187. Tonnesen, H.H. (2004). Photostability of Drugs and Drug Formulations. Taylor and Francis, New York.
188. TPD (1997). Stability Testing of Existing Drug Substances and Products. Therapeutic Products Directorate, Ottawa, Canada.
189. Tsong, Y. (2003). Recent issues in stability study introduction. Journal of Biopharmaceutical Statistics, 13, vii–ix.
190. Tsong, Y. Chen (2003a). ANOVA approach for shelf life analysis of stability study of multiple factor designs. Journal of Biopharmaceutical Statistics, 13, 375–393.
191. Tsong, Y. Chen, W.J., Lin, T.Y.D., and Chen, C.W. (2003b). Shelf life determination based on equivalence assessment. Journal of Biopharmaceutical Statistics, 13, 431–449.
192. Tsong, Y., Hammerstorm, T., Lin, K.K., and Ong, T.E. (1995). The dissolution testing sampling acceptance rules. Journal of Biopharmaceutical Statistics, 5, 171–184.
193. Tsong, Y., Hammerstrom, T., Sathe, P., and Shah, V.P. (1996). Statistical assessment of mean differences between two dissolution data sets. Drug Information Journal, 30, 1105–1112.
194. Tsong, Y., Shen, M., and Shah, V.P. (2004). Three-stage sequential statistical dissolution testing rules. Journal of Biopharmaceutical Statistics, 14, 757–779.
195. USP/NF (2000). The United States Pharmacopeia XXIV and the National Formulary XIX. The United States Pharmacopeial Convention, Inc., Rockville, MD.
196. Vonesh, E.F. and Carter, R.L. (1987). Efficient inference for random coefficient growth models with unbalanced data. Biometrics, 43, 617–628.
197. Wang, H. (2007). Estimation of the probability of passing the USP content uniformity test and the dissolution test. Journal of Biopharmaceutical Statistics, 17, No. 3. In press.
198. Wang, S.G. and Chow, S.C. (1994). Advanced Linear Models. Marcel Dekker, New York.
199. WHO. (1996). Guideline for Stability Testing of Pharmaceutical Products Containing well established drug substances in conventional dosage forms. In WHO Expert Committee on Specifications for Pharmaceutical Preparations. Technical Report Series 863, World Health Organization, Geneva, pp. 65–69.
200. WHO. (2006). WHO Working Document QAS/05.146: Stability Studies in a Global Environment. World Health Organization, Geneva.
201. Won, C.M. (1992). Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharamceutical Research, 9, 131–137.
202. Wright, J. (1989). Use of factorial designs in stability testing. In Proceedings of Stability Guidelines for Testing Pharmaceutical Products: Issues and Alternatives. AAPS Meeting, December, 1989.
203. Yoshioka, S. (1999). Current application in Japan of the ICH stability guideline: does Japanese registration require more than others do? In International Stability Testing, Mazzo, D., Ed. Interpharm Press, Buffalo Groove, IL, pp. 255–264.
204. Yoshioka, S., Aso, Y., and Kojima, S. (1997). Assessment of shelf-life equivalence of pharmaceutical products. Chemical and Pharmaceutical Bulletin, 45, 1482–1484.
205. Yoshioka, S. and Stella, V.J. (2000). Stability of Drugs and Dosage Forms. Springer, New York.